Intron-Retention Neoantigen Load Predicts Favorable Prognosis in Pancreatic Cancer

Chuanpeng Dong, MS1,2; Jill L. Reiter, PhD1,3; Edward Dong1; Yue Wang, PhD3; Kelvin P. Lee, MD4,5; Xiongbin Lu, PhD1,3,5; and Yunlong Liu, PhD1,2,3,5

abstract

PURPOSE High tumor mutation burden (TMB) in many cancer types is associated with the production of tumor-specific neoantigens, a favorable outcome and response to immune checkpoint blockade (ICB) therapy. Besides mutation-derived neoantigens, aberrant intron retention also produces tumor neopeptides that could trigger an immune response. The relationship between intron-retention–derived tumor neoantigens (IR-neoAg) and clinical outcomes in pancreatic cancer remains uncertain. Here, we quantify IR-neoAg in pancreatic cancer and evaluate whether IR-neoAg load might serve as a biomarker for selecting patients who may benefit from ICB therapy.

METHODS We developed a computational approach to estimate patient-specific IR-neoAg load from transcriptome data available in The Cancer Genome Atlas pancreatic cancer cohort. Associations between IR-neoAg load and patient overall survival were evaluated using Kaplan-Meier estimates and Cox regression. Differential expression of immune checkpoint and HLA-I genes was evaluated in tumors with high IR-neoAg load.

RESULTS High IR-neoAg load predicted better overall survival in pancreatic cancer, although no association was found for TMB. IR-neoAg load remained a significant prognostic factor after adjusting for patient age, sex, tumor stage and grade, and TMB. Moreover, pancreatic tumors with both high IR-neoAg load and high HLA-I gene expression had similar gene expression profiles as other tumor types that showed response to anti–programmed cell death protein 1 therapy.

CONCLUSION IR-neoAg load is associated with favorable survival in pancreatic cancer. These findings provide strong evidence for considering IR-neoAgs when selecting patients who might benefit from ICB therapy.

INTRODUCTION Advances in immune checkpoint blockade (ICB) therapy using antibodies that block programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4) have resulted in remarkable clinical responses in a wide variety of patients with cancer.1-3 Response to ICB therapy correlates with high tumor mutation burden (TMB) and the cell surface display of tumor neoantigens by major histocompatibility complex (MHC) molecules, which is critical for T-cell recognition and immune-mediated killing of tumor cells.4-7 Pancreatic cancer consists of two categories, namely cancers developing from the exocrine cells that make up the exocrine glands and ducts of the pancreas and cancers that develop from cells in the endocrine glands. More than 95% of pancreatic cancers arise from exocrine cells, with pancreatic ductal adenocarcinoma (PDAC) being the most common histologic type, as well as one of the deadliest with a 5-year survival rate < 8%.6 PDAC is considered an immune-privileged tumor and to date, ICB therapy has not shown efficacy in patients with PDAC, nor affected overall survival (OS).9,10 One explanation for why PDAC responds poorly to ICB therapy is a low TMB.11 However, recent studies have shown that some PDAC tumors do express neoantigens and exhibit T-cell infiltration.12,13 These findings imply that some patients are able to generate an antitumor immune response and, therefore, may benefit from ICB therapy.

In addition to somatic DNA mutations, aberrant RNA transcripts can be a major source of neopeptides when retained introns are translated and degraded through the nonsense-mediated decay mechanism.14 Intron retention (IR) commonly occurs in a wide variety of cancer transcriptomes, including PDAC, compared with normal tissues.15,16 Additionally, high IR levels in PDAC appears to be an independent predictor of tumor progression.17 Therefore, we hypothesized that in the presence of low TMB, aberrant IR-induced neoantigens
**CONTEXT**

**Key Objective**
Our aim was to use a bioinformatics approach to predict tumor-specific neoantigens that are derived from retained intron sequences in publicly available transcriptome data. We asked whether the level of intron-retention neoantigens (IR-neoAg) could predict a favorable outcome in patients with pancreatic cancer.

**Knowledge Generated**
We found that the IR-neoAg load is an independent predictor of overall survival in patients with pancreatic cancer. In addition, a subset of tumors with high IR-neoAg load and high HLA class-I gene expression showed an immune response consisting of infiltrating cytotoxic T cells, and also had transcriptome profiles similar to immune checkpoint blockade therapy–responsive tumors.

**Relevance**
RNA sequencing data from patient tumor samples can be used to evaluate intron retention and HLA-I gene expression. These two tumor markers could be potentially important for selecting patients with pancreatic cancer who might benefit from immune checkpoint blockade therapy.

(IR-neoAg) contribute to immune-mediated clearance of pancreatic cancer cells.

To begin to test this hypothesis, we herein used in silico prediction on RNA-sequencing data from two large independent cohorts of patients with pancreatic cancer from The Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium (ICGC) pancreatic cancer cohorts to determine whether IR-neoAg load was associated with longer OS for these patients. We also estimated tumor-infiltrating immune cell proportions and determined the association of IR-neoAgs with various tumor lymphocyte populations. In addition, we investigated the association of IR-neoAg load with expression of immune checkpoint genes and HLA genes encoding the MHC class-I molecules in pancreatic cancer. Finally, we compared gene expression profiles in pancreatic cancer with those of melanoma tumors that responded to anti–PD-1 checkpoint therapy. The results from this study could be useful in selecting patients with pancreatic cancer who might benefit from ICB therapy.

**METHODS**

**Pancreatic Cancer and Normal Pancreas Data Sets**
RNA-seq data from TCGA-PAAD (N = 178) with clinical and pathologic characteristics were downloaded from the Genomic Data Commons.\(^{18}\) RNA-seq data from the ICGC Pancreatic Cancer cohorts (ICGC-PDAC-AU, N = 81) were downloaded from the ICGC data portal.\(^{19}\) One sample each from TCGA-PAAD and ICGC-PDAC-AU cohorts was missing survival event time and was excluded from survival analyses. RNA-seq data from normal pancreas samples (n = 68) were retrieved from genotype-tissue expression (GTEx) projects.\(^{20}\) Four PDAC microarray data sets, GSE15471, GSE16515, GSE28735, and GSE62452,\(^{21-24}\) were downloaded from the GEO database, and the Bioconductor affy package was used for raw data processing and normalization.

**Identification of IR Events**
Raw fastq files were aligned to GRCh38 reference genome using STAR (v.2.7.2).\(^{25}\) The exon sets for each protein-coding gene were reannotated using GTF files (Gencode.v32). The union of each exon set was used to define introns as the interval between exon sets (Data Supplement). Exons and introns were quantified using uniquely mapped reads on the basis of the reannotated GTF file using HTseq.\(^{26}\) IR events were further filtered using the following criteria: (1) both the intron region and its flanking exon regions had read counts > 10 and (2) the transcripts per million ratios of the intron to flanking exons was > 0.05 and < 0.5. These filters allowed identification of IR events that had expression levels that were comparable with the flanking exons in the messenger RNA transcripts that were composed of a mixture of normal and aberrant splicing products. IR events that were also observed in at least 25% of normal pancreas RNA-seq data sets from GTEx\(^{20}\) were filtered to obtain the final set of pancreatic tumor-specific IR events.

**IR Neoantigen Prediction**
To obtain the set of neopeptides derived from retained introns, the open reading frames of the upstream exons were extended into introns until the first stop codon. The translated peptides were segmented into fragments of 8-11 amino acids that contained at least one intron-encoded amino acid. We estimated the binding affinity of each IR-derived neoepitope with specific MHC class-I molecules for each sample using NetMHCpan (v.4.1).\(^{27}\) Each patient's HLA genotype was deduced from RNA-seq data using arcasHLA (v1.1).\(^{28}\) NetMHCpan compares raw prediction scores to a set of random natural peptides to calculate the % rank, which provides robust binding metrics.\(^{27}\) Neopeptides with % rank < 0.5 were defined as strong binders, as recommended by NetMHCpan, and were considered as IR-neoAgs in this study.
Tumor Immune Cell Proportions and Prediction of Immunotherapy Response

The relative proportion of 22 types of tumor-infiltrating immune cells were inferred from bulk RNA-seq expression data using the online CIBERSORT application, with parameters set as LM22 signatures and 100 permutations. We used SubMap to evaluate the similarity between global gene expression patterns of TCGA-PAAD tumors with either high or low IR-neoAgs and samples from immunotherapy-treated melanoma patients. The mapping information generated by SubMap identifies subclasses common to two independent data sets and calculates the probability that they share similar biologic properties. Default parameters were used.

Differential Expression and Pathway Enrichment Analysis

Salmon (v1.2.1) was used to quantify the gene expression levels from RNA-seq data, using the reference annotation GRCh38 (genecode.v32). Differentially expressed genes among patient groups were identified with the limma package in R. The clusterProfiler package was used to test the pathway enrichment significance. P values were adjusted using the Benjamini-Hochberg method.

Statistical Analysis

All analyses and visualization were performed in R (v.4.0.2). Kaplan-Meier survival estimates and Cox proportional hazard analysis were performed with log-rank test and hazard ratio (HR) to compare patient groups, using the Survival package. Mann-Whitney-Wilcoxon test was used to compare differences in the value distribution between groups.

RESULTS

IR is a Potential Source of Neoantigens in PDAC

We first surveyed PDAC primary tumors in the TCGA SpliceSeq database to examine the frequency of IR compared with other alternative splicing events. We found that IR accounted for 16.5% of all alternative splicing events, which was second behind skipped exon (56%) and more common than alternative 5′- and 3′-splice site and mutually exclusive exons (13.7%, 12.1%, and 0.7%, respectively). Using Kyoto Encyclopedia of Genes and Genomes gene set enrichment analysis, we also found that the spliceosome pathway was significantly upregulated in PDAC compared with adjacent normal tissue (Data Supplement). These findings are consistent with those of Wang et al, who first reported the frequency of different alternative splicing events and dysregulation of the spliceosome machinery using Affymetrix exon array data from PDAC tissues.

Next, we investigated the immunogenic potential of IR-derived neopeptides using RNA-seq data from 178 pancreatic cancer patient samples in the TCGA-PAAD cohort. An overview of the data processing steps in our computational pipeline to identify IR events and IR-neoAgs is diagrammed in Figure 1A. IR events were first identified in 68 normal pancreas GTEx RNA-seq data sets. We found a total of 5,927 IR events that occurred in at least 25% of the GTEx samples (Data Supplement). After filtering these normal IR events, there were an average of 600 tumor-specific IR events per sample. Each patient’s HLA genotype was further deduced from RNA-seq data (Data Supplement) and used to predict the number of IR-neoAgs in their tumor sample. A total of 171,526 IR-neoAgs were predicted with an average IR-neoAg load of 963 (range 43-4,284) per tumor sample (Data Supplement). The number of IR-neoAgs per tumor was strongly correlated with the number of IR events (Spearman correlation rho = 0.93, P < .001, Fig 1B). Interestingly, the predicted number of IR-neoAgs presented by each HLA type was not related to HLA allele frequency (Fig 1C). For example, HLA-A02:01 showed the highest allele frequency (24.2%), but this allele was only predicted to present 11,014 (6.4%) of the IR-neoAg peptides. By contrast, HLA-B07:02 had a lower allele frequency (8.7%) but was predicted to present 23,481 (13.7%) IR-neoAgs. These findings suggest that a patient’s HLA genotype is an important factor in predicting immunogenicity of potential IR-neoAgs.

IR-neoAg Load Is an Independent Prognostic Factor for Pancreatic Cancer

TCGA-PAAD tumors (N = 178) were divided into high and low IR-neoAg groups on the basis of the median IR-neoAg number. The high and low IR-neoAg groups were not significantly different with respect to age, sex, tobacco smoking, or for clinical features such as tumor stage, grade, or microsatellite instability (Table 1). However, the median OS time for patients with high IR-neoAg load was 24 months compared with 19 months for those with low IR-neoAg load (Kaplan-Meier log-rank test, P = .011; Fig 1D). The association between high IR-neoAg load and survival was independent of clinicopathologic factors (P = .008, multivariate Cox regression analysis; Table 2). The HR was 0.55, indicating that high IR-neoAg load reduced the risk of poor outcome by 45%. High IR-neoAg load was also associated with longer survival in the ICGC PDAC cohort (N = 81), although these findings did not reach statistical significance likely because of the smaller sample size (Data Supplement).

Our findings agree with those of Tan et al, who showed that IR was associated with PDAC patient outcome in a curated subset of the TCGA-PAAD cohort (n = 150), which excluded non-PDAC tumors such as acinar cell carcinoma, pancreatic neuroendocrine tumors (PanNET), benign neoplasms, and tumors with < 1% neoplastic cellularity. Since our initial survival analysis was performed using all 178 TCGA-PAAD samples with RNA-seq data, we repeated the multivariate Cox regression analysis on the curated set of 150 PDAC samples and considered tumor purity as a covariate. Our results showed that high IR-neoAg load remained significantly associated with longer OS (HR,
These results, taken together, support IR and IR-neoAg load as independent predictors of pancreatic cancer progression and patient survival.

**IR-neoAg Load Is Associated With Features of Tumor Immune Response**

To test whether high IR-neoAg load was accompanied by immune cell infiltration in the TCGA cohort, we used a deconvolution algorithm to estimate the relative percentages and activation states of 22 types of immune cells from bulk RNA-seq data.29 Seven cell types showed statistically significant differences between high and low IR-neoAg load tumors (Fig 2A). There were more memory B cells ($P = .014$), follicular helper T (Tfh) cells ($P = .011$), and naive CD4+ T cells ($P = .044$) in tumors with high IR-neoAg load. By contrast, these tumors had fewer resting mast cells ($P = .002$), resting dendritic cells ($P = .011$), M1-macrophages ($P = .013$), and neutrophils ($P = .003$). However, no significant correlation was observed between IR-neoAg load and the relative percentage of CD8+ T cells or other cytotoxic immune cell types (Data Supplement). Although the overall percentage of infiltrating immune cells was low, higher levels of memory B and Tfh cells are generally associated with better prognosis and cancer immunotherapy response.40-42 These findings imply that IR-neoAg load may affect the immune cell composition of the tumor microenvironment (TME).
To better understand the molecular differences that might contribute to OS between pancreatic cancers with high and low IR-neoAg load, we compared the expression levels of a collection of genes related to immune cell response, consisting of nine B7 ligand genes, five B7 receptor genes, six MHC-I genes, and nine MHC-II genes. We found that 12 of 14 B7 ligand and receptor genes had lower expression in samples with high IR neoAg load, with CD86 and PD-L2 reaching statistical significance (Fig 2B). In addition, all nine MHC-II genes were expressed at lower levels in the high IR-neoAg group, with eight of nine reaching statistical significance. Only one MHC-I pathway gene, TAPBP, showed significant differential expression between tumors with high and low IR-neoAg load. Thus, longer OS in patients with high IR-neoAg load tumors could be partially explained by low expression levels of immune coinhibitory genes that dampen effector T-cell responses.

**TABLE 1.** Clinical and Pathologic Characteristics of TCGA-PAAD Data Set

| Characteristics            | No. | Low IR-neoAg Load (%) | High IR-neoAg Load (%) | P     |
|----------------------------|-----|-----------------------|------------------------|-------|
| Age, years                 |     |                       |                        |       |
| Median                     | 65  | 65                    | 65                     |       |
| IQR                        | 57-73| 57-74                 | 56-72                  |       |
| ≤ 60 (65)                  | 59  | 29 (32.6)             | 30 (33.7)              | .999  |
| > 60 (59)                  | 119 | 60 (67.4)             | 59 (66.3)              |       |
| Sex                        |     |                       |                        |       |
| Female                     | 80  | 41 (46.1)             | 39 (43.8)              | .880  |
| Male                       | 98  | 48 (53.9)             | 50 (56.2)              |       |
| Tumor stage                |     |                       |                        |       |
| I-II                       | 168 | 83 (93.3)             | 85 (95.5)              | .859  |
| III-IV                     | 8   | 5 (5.6)               | 3 (3.3)                |       |
| Unknown                    | 2   | 1 (1.1)               | 1 (1.1)                |       |
| Tumor grade                |     |                       |                        |       |
| G1 + G2                    | 126 | 61 (68.5)             | 65 (73.0)              | .807  |
| G3 + G4                    | 50  | 27 (30.3)             | 23 (25.8)              |       |
| Unknown                    | 2   | 1 (1.1)               | 1 (1.1)                |       |
| MSI/MSS status             |     |                       |                        |       |
| MSS                        | 141 | 68 (76.4)             | 73 (82.0)              | .169  |
| Indeterminate              | 28  | 18 (20.2)             | 10 (11.2)              |       |
| MSI-L                      | 9   | 3 (3.4)               | 6 (6.7)                |       |
| Smoking status*            |     |                       |                        |       |
| No                         | 121 | 63 (70.8)             | 58 (65.2)              | .521  |
| Yes                        | 57  | 26 (29.2)             | 31 (34.8)              |       |

Abbreviations: G, grade; IQR, interquartile range; IR-neoAg, intron-retention neoantigens; MSI, microsatellite instability; MSI-L, microsatellite instability-low; MSS, microsatellite stable; TCGA, The Cancer Genome Atlas.

*Smoking status was characterized as smoking exposure by pack-years > 1.

To better understand the molecular differences that might contribute to OS between pancreatic cancers with high and low IR-neoAg load, we compared the expression levels of a collection of genes related to immune cell response, consisting of nine B7 ligand genes, five B7 receptor genes, six MHC-I genes, and nine MHC-II genes. We found that 12 of 14 B7 ligand and receptor genes had lower expression in samples with high IR neoAg load, with CD86 and PD-L2 reaching statistical significance (Fig 2B). In addition, all nine MHC-II genes were expressed at lower levels in the high IR-neoAg group, with eight of nine reaching statistical significance. Only one MHC-I pathway gene, TAPBP, showed significant differential expression between tumors with high and low IR-neoAg load. Thus, longer OS in patients with high IR-neoAg load tumors could be partially explained by low expression levels of immune coinhibitory genes that dampen effector T-cell responses.

**TABLE 2.** Univariate and Multivariate Cox Regression Analyses of Overall Survival in TCGA-PAAD Patients

| Variable                                      | Univariate Analysis | Multivariate Analysis |
|-----------------------------------------------|---------------------|-----------------------|
|                                               | HR  | 95% CI of HR | P      | HR  | 95% CI of HR | P      |
| IR-neoAg (high/low)                           | 0.586 | 0.386 to 0.890 | .012   | 0.549 | 0.353 to 0.854 | .008   |
| Age, years                                    | 1.028 | 1.007 to 1.049 | .009   | 1.023 | 1.003 to 1.045 | .028   |
| Sex (male/female)                             | 0.824 | 0.548 to 1.238 | .350   | 0.959 | 0.617 to 1.492 | .853   |
| Stage (I/II/III/IV)                           | 1.301 | 0.889 to 1.904 | .175   | 1.211 | 0.801 to 1.830 | .364   |
| Grade (1/2/3/4)                                | 1.448 | 1.089 to 1.925 | .011   | 1.27  | 0.933 to 1.731 | .129   |
| MSI status (indeterminate/MSS/MSI-L)          | 1.111 | 0.659 to 1.872 | .694   | 1.477 | 0.859 to 2.541 | .158   |
| TMB                                           | 1.000 | 0.999 to 1.000 | .660   | 1.000 | 1.000 to 1.0002 | .918 |

NOTE. TMB is the count of nonsynonymous mutations.

Abbreviations: HR, hazard ratio; IR-neoAg, intron-retention neoantigens; MSI, microsatellite instability; MSS, microsatellite stable; TCGA, The Cancer Genome Atlas; TMB, tumor mutation burden.
analysis showed that all eight PanNET patients in the TCGA-PAAD cohort fell into this category and were among the patients with the longest OS.

**IR-neoAg Load and HLA-I Expression Identify a Subgroup of Tumors That Have Similar Gene Expression Patterns as Tumors That Respond to ICB Therapy**

Tumor neoantigens are critical mediators of host immune response and immunotherapy treatment efficacy. In addition, MHC class-I expression is essential for neoantigen presentation. Because ICB therapy has not been used routinely for patients with PDAC, we used SubMap, a sub-class mapping method, to determine whether TCGA-PAAD tumors with high IR-neoAg load and high HLA-I gene expression levels shared similar transcriptomic profiles with ICB therapy–responsive melanoma tumors. We calculated an HLA-I score for each TCGA-PAAD tumor sample by averaging the expression value of the three major HLA genes, HLA-A, -B, and -C (Data Supplement). We then divided the samples into two groups on the basis of the number of IR-neoAg and the HLA-I score. One group contained samples with higher than the median IR-neoAg and HLA-I score, denoted as IR-neoAg<sup>hi</sup>-HLA-I<sup>hi</sup> (n = 43) and the other group consisted of all other tumors (n = 135). Notably, SubMap analysis indicated that the gene expression profiles of the IR-neoAg<sup>hi</sup>-HLA-I<sup>hi</sup> group showed significant similarity with the subset of melanoma tumors that were responsive to anti–PD-1 immunotherapy (Fig 3A, Bonferroni-corrected post hoc tests).

**FIG 2.** IR-neoAg load is associated with immune features in the TCGA-PAAD cohort. (A) Comparison of the percentage of tumor-infiltrated immune cells between tumors with high and low IR-neoAg load. A positive value along the x-axis represents a higher and a negative value represents a lower proportion of cells in the high IR-neoAg samples. *P* values were calculated using the Mann-Whitney-Wilcoxon test. (B) Volcano plot showing the expression differences of immune-related genes between the high and low IR-neoAg load tumors. Symbols to the right of the vertical dashed line represent genes with higher expression and symbols on the left represent genes with lower expression in high IR-neoAg tumors. Symbols above the red dashed line represent genes with adjusted *P*-values < .05. Kaplan-Meier overall survival curves for four patient groups stratified by IR-neoAg load and the gene expression levels of (C) PD-L1, (D) PD-1, and (E) CTLA4. A risk table is displayed below the plot. CTLA4, cytotoxic T-lymphocyte antigen 4; IR-neoAg, intron-retention neoantigens; OS, overall survival; PD-1, programmed cell death protein 1; PD-L1, programmed cell death ligand 1.
Intron-Retention Neoantigens in Pancreatic Cancer

... with PD-1, PD-L1, or CTLA-4 expression and the anti-PD-1 responsive melanoma samples (data not shown). Notably, 93% of the IR-neoAg \textsuperscript{hi}-HLA-I\textsuperscript{hi} tumors (40 of 43) were classified as PDAC; three tumors were excluded from the curated 150 TCGA-PAAD set, which included two samples with low neoplastic cellularity and one tumor that did not arise from the pancreas. We also found that CD8+ T cells, as well as the total number of tumor-infiltrating immune cells, were both significantly higher in IR-neoAg \textsuperscript{hi}-HLA-I\textsuperscript{hi} samples compared with the other tumors (Fig 3B, Wilcoxon test, \(P < .001\)). Furthermore, this set of IR-neoAg \textsuperscript{hi}-HLA-I\textsuperscript{hi} tumors had significantly higher expression of PD-1 and PD-L1 genes (Fig 3C), which likely reflects the higher proportion of CD8+ T cells and other cytotoxic immune cells. Together, these results indicate that patients with pancreatic cancer with IR-neoAg \textsuperscript{hi}-HLA-I\textsuperscript{hi} tumors may represent a group that is more likely to respond to anti-PD-1 treatment.

**DISCUSSION**

We have shown that tumor-specific IR-neoAg load is an independent predictor of OS in patients with pancreatic cancer. In addition, we found that the subset of tumors with the combination of high IR-neoAg load and high HLA-I gene expression had transcriptome profiles with significant similarities to melanoma tumors that were responsive to anti-PD-1 therapy. This subset of IR-neoAg \textsuperscript{hi}-HLA-I\textsuperscript{hi} tumors showed higher numbers of tumor-infiltrating immune cells, including CD8+ T cells. Collectively, our findings suggest that IR-neoAg load identifies patients with better prognosis, and together with HLA-I expression levels, could be a useful biomarker for selecting patients who may benefit from ICB therapy.

TMB has emerged as a biomarker of response to ICB therapy because it is a source of tumor-specific neoantigens that are targets of activated immune cells. TMB and neoantigen load have been shown to correlate with patient response to ICB therapy in several cancer types.\textsuperscript{1,46-48} However, pancreatic cancer is characterized by a low TMB that frequently does not meet the threshold defined by clinical trials for ICB benefit.\textsuperscript{39,49,52} Like TMB, intron retention is also a source of tumor neoantigens that can be presented by MHC-I.\textsuperscript{14,53} Thus, in cancers with low TMB, IR-neoAgs could be a potentially important biomarker for selecting patients who might benefit from ICB therapy.

Importantly, additional factors other than neoantigens influence the ability of T cells to recognize and kill tumor cells. For example, the TME is an important factor in the poor responsiveness of PDAC to ICB therapy. PDAC TME is highly desmoplastic because of the presence of cancer-

![FIG 3.](image-url)

**FIG 3.** High IR-neoAg and high HLA class-I expression identify pancreatic cancers with similarities to tumors responsive to immune checkpoint blockade therapy. (A) Submap analysis comparing two groups from the TCGA-PAAD cohort (IR-neoAg \textsuperscript{hi}-HLA-I\textsuperscript{hi} \(n = 43\), and all Others \(n = 135\)) and four groups from an ICB-treated melanoma patient data set (anti-PD-1 responders \(n = 12\), anti-PD-1 nonresponders \(n = 14\), anti-CTLA-4 responders \(n = 8\), and anti-CTLA-4 nonresponders \(n = 28\)). Bonferroni-corrected \(P\) values were calculated in the SubMap program. (B) Box plot representation of the proportion of CD8+ T cells and total tumor-infiltrated immune cells between tumors with IR-neoAg \textsuperscript{hi}-HLA-I\textsuperscript{hi} and all other tumors in the TCGA-PAAD data set. Absolute score is estimated as the median expression level of all genes in the signature matrix divided by the median expression level of all genes in the mixture and is used to scale the relative cell fractions to absolute abundances. (C) Box plot representation of the tumor expression levels of immune checkpoint genes (PD-1 and PD-L1) in TCGA-PAAD tumors with IR-neoAg \textsuperscript{hi}-HLA-I\textsuperscript{hi} and all others. Box plots represent median and IQR. Upper whisker extends to the third quartile plus 1.5x IQR. Lower whisker extends to the first quartile minus 1.5x IQR. \(P\) values were determined using Wilcoxon test. CTLA-4, cytotoxic T-lymphocyte antigen 4; IQR, interquartile range; IR-neoAg, intron-retention neoantigens; mRNA, messenger RNA; PD-1, programmed cell death protein 1; PD-L1, programmed cell death ligand 1; TPM, transcripts per million.

JCO Clinical Cancer Informatics 7
associated fibroblasts and a dense extracellular matrix, which impedes drug delivery. Because most patients with PDAC present with advanced disease, combination therapies will undoubtedly be necessary for overcoming resistance and improving immunotherapy strategies. We provide evidence that IR-neoAgs may aid in advancing these efforts by providing a new tool for selecting patients for participation in future clinical trials.

REFERENCES

1. Rizvi NA, Hellmann MD, Snyder A, et al: Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348:124-128, 2015
2. Brahmer JR, Tykodi SS, Chow LQ, et al: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455-2465, 2012
3. Ji RR, Chasalow SD, Wang L, et al: An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother 61:1019-1031, 2012
4. Goodman AM, Castro A, Pyke RM, et al: MHC-I genotype and tumor mutational burden predict response to immunotherapy. Genome Med 12:45, 2020
5. Valero C, Lee M, Hoen D, et al: The association between tumor mutational burden and prognosis is dependent on treatment context. Nat Genet 53:11-15, 2021
6. Samstein RM, Lee CH, Shoushtari AN, et al: Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet 51:202-206, 2019
7. Hendriks LE, Rouleau E, Besse B: Clinical utility of tumor mutational burden in patients with non-small cell lung cancer treated with immunotherapy. Transl Lung Cancer Res 7:647-660, 2018
8. Ort M, Metzger P, Gerum S, et al: Pancreatic ductal adenocarcinoma: Biological hallmarks, current status, and future perspectives of combined modality treatment approaches. Radiat Oncol 14:141, 2019
9. Amin S, Baine MJ, Meza JL, et al: The association of the sequence of immunotherapy with the survival of unresectable pancreatic adenocarcinoma patients: A retrospective analysis of the National Cancer Database. Front Oncol 10:1518, 2020
10. Principe DR, Korc M, Kamath SD, et al: Trials and tribulations of pancreatic cancer immunotherapy. Cancer Lett 504:1-14, 2021
11. Maleki Vareki S: High and low mutational burden versus immunologically hot and cold tumors and response to immune checkpoint inhibitors. J Immunother Cancer 6:157, 2018
12. Balachandran VP, Luksza M, Zhao JN, et al: Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature 551:512-516, 2017
13. Hegde S, Krisnawan VE, Herzog BH, et al: Dendritic cell paucity leads to dysfunctional immune surveillance in pancreatic cancer. Cancer Cell 37:289-307.e9, 2020
14. Smart AC, Margolis CA, Pimentel H, et al: Intratumoral islet cell retention is a source of neoepitopes in cancer. Nat Biotechnol 36:1056-1058, 2018
